In Union Budget 2026-27, the Government announced Biopharma SHAKTI with an outlay of Rs.10,000 crore over five years, including three new NIPERs, upgradation of seven existing NIPERs, and a network of 1,000+ accredited clinical trial sites.
First mission-mode fiscal programme for advanced biologics manufacturing. Five-year funding certainty creates the fiscal architecture to reduce India's structural dependence on imported high-value biologics and biosimilars.